-
「同位素标记抑制剂」CAS:863653-47-8|N-Methylformamide-d5
作者：德尔塔生物 日期：2025-06-12
生物活性：N-Methylformamide-d5 is the deuterium labeled N-Methylformamide[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.N-Methylformamide-d5 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：64.10Formula：C2D5NOCAS 号：863653-47-8非标记 CAS：123-39-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (519 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:87955-92-8|N-Methylformamide-d3
作者：德尔塔生物 日期：2025-06-12
生物活性：N-Methylformamide-d3 is the deuterium labeled N-Methylformamide[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.N-Methylformamide-d3 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：62.09Formula：C2H2D3NOCAS 号：87955-92-8非标记 CAS：123-39-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:33975-46-1|Nonan-1-ol-d4
作者：德尔塔生物 日期：2025-06-12
生物活性：Nonan-1-ol-d4 is the deuterium labeled Nonan-1-ol[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：148.28Formula：C9H16D4OCAS 号：33975-46-1非标记 CAS：143-08-8中文名称：九碳醇-d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (515 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:349553-86-2|Nonan-1-ol-d19
作者：德尔塔生物 日期：2025-06-12
生物活性：n-Nonyl Alcohol-d19 is the deuterium labeled Nonan-1-ol[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：163.37Formula：C9HD19OCAS 号：349553-86-2非标记 CAS：143-08-8中文名称：九碳醇-d19运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1184999-77-6|Lansoprazole sulfone-d4
作者：德尔塔生物 日期：2025-06-12
生物活性：Lansoprazole sulfone-d4 (AG-1813-d4) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d4 is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone-d4 can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone-d4 has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease[1][2][3].分子量：389.39Formula：C16H10D4F3N3O3SCAS 号：1184999-77-6非标记 CAS：131926-99-3中文名称：兰索拉唑EP杂质B(Lansoprazole Sulfone) d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (526 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Swamy G, et al. Crystal structure of lansoprazole sulfone[J]. Journal of Structural Chemistry, 2007, 48: 715-718.[3]. Karol MD, et al. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Clin Pharmacol Ther. 1997 Apr;61(4):450-8. [Content Brief]
-
「同位素标记抑制剂」CAS:1219799-21-9|N-Dodecyl-N,N-dimethyldodecan-1-aminium-d5 bromide
作者：德尔塔生物 日期：2025-06-12
生物活性：N-Dodecyl-N,N-dimethyldodecan-1-aminium-d5 (bromide) is the deuterium labeled N-Dodecyl-N,N-dimethyldodecan-1-aminium bromide[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：247.47Formula：C16H29D5OCAS 号：1219799-21-9非标记 CAS：3282-73-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (513 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:918897-30-0|N-Dodecyl-N,N-dimethyldodecan-1-aminium-d25 bromide
作者：德尔塔生物 日期：2025-06-12
生物活性：N-Dodecyl-N,N-dimethyldodecan-1-aminium-d25 (bromide) is the deuterium labeled N-Dodecyl-N,N-dimethyldodecan-1-aminium bromide[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：487.79Formula：C26H31D25BrNCAS 号：918897-30-0非标记 CAS：3282-73-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:478529-64-5|(R)-2,3-Dihydroxypropanal-d
作者：德尔塔生物 日期：2025-06-12
生物活性：(R)-2,3-Dihydroxypropanal-d is the deuterium labeled (R)-2,3-Dihydroxypropanal[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：91.08Formula：C3H5DO3CAS 号：478529-64-5非标记 CAS：453-17-8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (519 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:478529-60-1|(R)-2,3-Dihydroxypropanal-d4
作者：德尔塔生物 日期：2025-06-12
生物活性：(R)-2,3-Dihydroxypropanal-d4 is the deuterium labeled (R)-2,3-Dihydroxypropanal[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：94.10Formula：C3H2D4O3CAS 号：478529-60-1非标记 CAS：453-17-8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (522 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:478529-58-7|(R)-2,3-Dihydroxypropanal-d2
作者：德尔塔生物 日期：2025-06-12
生物活性：(R)-2,3-Dihydroxypropanal-d2 is the deuterium labeled 3-O-Methyl-D-glucopyranose[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：92.09Formula：C3H4D2O3CAS 号：478529-58-7非标记 CAS：453-17-8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1092484-56-4|Fenofibrate-d6
作者：德尔塔生物 日期：2025-06-12
生物活性：Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.IC50 & Target：CYP2CYP3体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Fenofibrate-d6 相关抗体:PPAR alpha AntibodyCytochrome C AntibodyPPAR gamma AntibodyPPAR gamma Antibody (YA122)Cytochrome P450 17A1 AntibodyAromatase AntibodyCYP11A1 AntibodyCytochrome P450 1B1 Antibody (YA1836)Adrenodoxin Antibody (YA2005)Cytochrome P450 27A1 Antibody (YA2163)Cytochrome P450 2C9 Antibody (YA2166)Cytochrome P450 2E1 Antibody (YA2302)Cytochrome P450 Reductase Antibody (YA2619)Thromboxane A Synthase Antibody (YA2670)Cytochrome P450 3A4 Antibody (YA3365)HSD11B1 Antibody (YA3376)Cytochrome P450 17A1 Antibody (YA786)CYP2E1 AntibodyCYP1A2 AntibodyPGC1 beta Antibody (YA1411)PLSCR3 Antibody (YA1672)PROX1 Antibody (YA1754)Cytochrome P450 4A Antibody (YA2087)Cytochrome P450 24A1 Antibody (YA2121)Cytochrome P450 26A1 Antibody (YA2259)COX5B Antibody (YA2550)Steroidogenic Factor 1 Antibody (YA3166)Dynein Light Chain Tctex Type 1 Antibody (YA3263
-
「同位素标记抑制剂」CAS:2702798-58-9|Pramipexole-d7-1 dihydrochloride
作者：德尔塔生物 日期：2025-06-12
生物活性：Pramipexole-d7-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Pramipexole-d7-1 dihydrochloride 相关抗体:DRD2 AntibodyDopamine Receptor D3 Antibody (YA1742)DOPA Decarboxylase Antibody (YA2428)Dopamine Receptor D1 Antibody (YA3270)Torsin 1A Antibody (YA2935)PITX3 Antibody (YA2974)HMBS Antibody (YA3061)分子量：254.83Formula：C10H11D7ClN3SCAS 号：2702798-58-9非标记 CAS：104632-25-9中文名称：盐酸普拉克索-d7-1；盐酸米拉帕-d7-1运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2)
-
「同位素标记抑制剂」CAS:1398065-63-8|Loratadine-d5
作者：德尔塔生物 日期：2025-06-12
生物活性：Loratadine-d5 is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-dengue-virus (DENV) activity. Loratadine can inhibit immunologic release of inflammatory mediators.IC50 & Target：H1 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Loratadine-d5 相关抗体:ADGRE1 (F4/80) Antibody (YA002)ADGRE1 (F4/80) Antibody (YA920)分子量：387.91Formula：C22H18D5ClN2O2CAS 号：1398065-63-8非标记 CAS：79794-75-5性状：固体颜色：White to off-white中文名称：氯雷他定 d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month
-
「同位素标记抑制剂」CAS:2070015-04-0|Cetirizine-d8 dihydrochloride
作者：德尔塔生物 日期：2025-06-12
生物活性：Cetirizine-d8 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].IC50 & Target：H1 Receptor分子量：469.86Formula：C21H19D8Cl3N2O3CAS 号：2070015-04-0非标记 CAS：83881-52-1中文名称：盐酸西替利嗪 d8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (532 KB)产品使用指南 (1538 KB)参考文献[1]. Caroline M. Spencer, et al. Cetirizine. Drugs 46 (6): 1055•1080, 1993.[2]. Shih MY, et al. Influence of cetirizine and levocetirizine on two cytokines secretion in human airway epithelial cells. Allergy Asthma Proc. 2008 Sep-Oct;29(5):480-5. [Content Brief][3]. Shimizu T, et al. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy. 2004 Jan;34(1):103-9. [Content Brief]
-
「同位素标记抑制剂」CAS:922731-04-2|Esomeprazole-d6 sodium
作者：德尔塔生物 日期：2025-06-12
生物活性：Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Esomeprazole-d6 sodium 相关抗体:PMCA1 Antibody (YA1676)分子量：374.44Formula：C17H13D6N3NaO3SCAS 号：922731-04-2非标记 CAS：161796-78-7中文名称：埃索美拉唑钠-d6； 艾司奥美拉唑钠-d6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief][3]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-In
咨询热线
18133906270
德尔塔官方微信